Biocardia doses first patient in cardiallo phase i/ii clinical trial of bcda-03 allogeneic mesenchymal stem cells for the treatment of ischemic heart failure of reduced ejection fraction

Sunnyvale, calif., dec. 19, 2023 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced that the first patient was enrolled and treated in its cardiallo™ allogeneic mesenchymal cell therapy phase i/ii trial for the treatment of patients with new york heart association class ii and iii ischemic heart failure of reduced ejection fraction (hfref).
BCDA Ratings Summary
BCDA Quant Ranking